Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07377929 · ClinicalTrials.gov registry record
Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms
A clinical trial of Lower Urinary Track Symptoms and Benign Prostatic Hypertrophy (BPH), sponsored by Benaroya Research Institute.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT07377929 is a study of Lower Urinary Track Symptoms and Benign Prostatic Hypertrophy (BPH) that is actively recruiting participants, run by Benaroya Research Institute. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07377929, a study of Lower Urinary Track Symptoms and Benign Prostatic Hypertrophy (BPH), is actively recruiting participants, sponsored by Benaroya Research Institute.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with longstanding obstructive lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH) can also develop symptoms of overactive bladder syndrome (OAB). Transurethral resection of the prostate (TURP) and Transurethral Waterjet Ablation of the Prostate (Aquablation) are amongst the gold standard surgical treatments for BPH. However, in the immediate post-operative period, TURP and Aquablation can also include OAB-like symptoms, including urinary frequency and urgency. For men with baseline OAB symptoms, this initial worsening of symptoms can be distressing. Botox is an FDA approved medication with on-label indications to treat overactive bladder. The purpose of this study is to evaluate the outcomes of men who have Botox concurrent with their TURP or Aquablation.
Conditions Studied
Interventions
- OTHER Survey using a questionnaire.
Study Locations (1)
Washington
- Virginia Mason Franciscan Health - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-19 |
| Est. Completion | 2027-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07377929
The ClinicalTrials.gov registry entry for NCT07377929 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Benaroya Research Institute, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lower Urinary Track Symptoms appearing as the primary indexed condition, and to 1 intervention - of which Survey using a questionnaire. is the first listed.
NCT07377929 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT07377929 about?
NCT07377929 is a clinical study titled "Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms". Patients with longstanding obstructive lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH) can also develop symptoms of overactive bladder syndrome (OAB). Transurethral resection of the prostate (TURP) and Transurethral Waterjet Ablation of the Prostate (Aquablation) are am...
What is the current status of trial NCT07377929?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2026-01-19. Estimated completion is 2027-05-01.
What conditions does trial NCT07377929 study?
This clinical trial studies the following conditions: Lower Urinary Track Symptoms, Benign Prostatic Hypertrophy (BPH).
What interventions are being tested in trial NCT07377929?
The interventions under investigation include: Survey using a questionnaire. (OTHER).
Who is sponsoring clinical trial NCT07377929?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07377929 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lower Urinary Track Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Lower Urinary Track Symptoms
All registered trials for this condition
Benign Prostatic Hypertrophy (BPH)
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.